

## References

### I-129

1. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. *Ther Adv Gastroenterol.* 2015;8(2):66–82.
2. Kawalec P, Mocko P, Pil A, et al. Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison. *Pharmacotherapy.* 2016;861-869.
3. Daumgart DC, Bokemeyer B, Brabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study. *Alimentary Pharmacology and Therapeutics.* 2016;1090-1102.
4. Singh H, Grewal N, Kumar EAH, Kakkar AK. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. *Journal of Natural Science, Biology & Medicine.* 2016;4-9.
5. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare.* 2016.
6. Schneider AM, Weghuber D, Hetzer B, Entenmann A, Muller T, Zimmermann G, et al. Vedolizumab use after failure of TNF-alpha antagonists in children and adolescents with inflammatory bowel disease. *BMC Gastroenterology.* 2018;18(140):1-7.
7. Garnock-Jones, KP. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or crohn's disease. *BioDrugs.* 2015;29:57-67.
8. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and crohn's disease. *Gut.* 2017;66(5):839-851.
9. MICROMEDEX®SOLUTIONS Compendia. 2019. Vedolizumab.
10. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Vedolizumab. 2019.

11. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
12. Lightner AL, McKenna NP, Tse CS, Raffals LE, Loftus J. EV, Mathis KL. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. *Alimentary Pharmacology & Therapeutics*. 2018;47(5):573-580.
13. Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*. 2017;45(7):941-950.
14. Entyvio (vedolizumab) for injection, for intravenous use [package insert]. Takeda Pharmaceuticals America, Inc. Deerfield, IL. Revised 05/2019.
15. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114:384-413.
16. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of crohn's disease in adults. *Am J Gastroenterol*. 2018;113:481–517.
17. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. *Gastroenterology*. 2019;156:1508-1524.